Cerevel Therapeutics Holdings Inc

+0.90 (+3.45%)
Products, Regulatory

Cerevel Therapeutics Announces Positive Topline Results For Cvl-231 In Phase 1B Clinical Trial In Patients With Schizophrenia

Published: 06/29/2021 10:41 GMT
Cerevel Therapeutics Holdings Inc (CERE) - Cerevel Therapeutics Announces Positive Topline Results for Cvl-231 in Phase 1b Clinical Trial in Patients With Schizophrenia.
Cerevel Therapeutics - Both Doses of Cvl-231 Demonstrated Clinically Meaningful, Statistically Significant Improvement in Panss Total Score at 6 Weeks.
Cerevel Therapeutics Holdings Inc - Both Doses of Cvl-231 Were Overall Well-tolerated Compared With Placebo.
Cerevel Therapeutics - No Meaningful Differences in Gastrointestinal Side Effects, Extrapyramidal Symptoms Or Weight Gain Compared With Placebo.
Cerevel - Plans to Advance Cvl-231 to Phase 2 in Schizophrenia and to Evaluate Potential in Other Populations, Including Dementia-related Psychosis.